Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

Delie, A.; Verlinden, A.; Beel, K.; Deeren, D.; Mazure, D.; Baron, Frédéric; Breems, D.; De Becker, A.; Graux, C.; Lewalle, Philippe; Maertens, J.; Poire, X.; Schoemans, H.; Selleslag, D.; Van Obbergh, F.; Kerre, T.

doi:10.1080/17843286.2020.1754635

Article (Scientific journals)

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

Delie, A.; Verlinden, A.; Beel, K. et al.

2021 • In Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, 76, p. 500-508

Peer reviewed

Permalink
https://hdl.handle.net/2268/256135

DOI
10.1080/17843286.2020.1754635

PubMed
32362204

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Use of chimerism analysis after allogeneic stem cell transplantation Belgian guidelines and review of the current literature.pdf

Publisher postprint (1.04 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Allogeneic stem cell transplantation

Abstract :

[en] Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option in both adult and pediatric patients with malignant and non-malignant hematological diseases. Chimerism analysis, which determines the donor or recipient origin of hematopoietic cells in HSCT recipients, is an essential aspect of post-HSCT follow-up.Objectives: To review the current literature and develop Belgian consensus guidelines for the use of chimerism analysis in the standard of care after allogeneic HSCT.Methods: Non-systematic review of the literature in consultancy with the members of the BHS transplantation committee.Results: Clinical application with regards to prediction of graft failure or relapse as well as cell source are reviewed. A consensus guideline on the use of chimerism analysis after HSCT is presented.Conclusion: Monitoring of the dynamics or kinetics of a patient’s chimerism status by serial analysis at fixed time points, as well as on suspicion of relapse or graft failure, is needed to monitor engraftment levels, as well as disease control and possible relapse. © 2020, © 2020 Journal of Belgian Society of Internal Medicine and Royal Belgian Society of Laboratory Medicine.

Disciplines :

Hematology

Author, co-author :

Delie, A.; Department of Hematology, University Hospital, Ghent University, Ghent, Belgium

Verlinden, A.; Department of Hematology, University Hospital, University of Antwerp, Antwerp, Belgium

Beel, K.; Department of Hematology, Ziekenhuis Netwerk, Antwerpen, Belgium

Deeren, D.; Department of Hematology, AZ Delta, Roeselare, Belgium

Mazure, D.; Department of Hematology, University Hospital, Ghent University, Ghent, Belgium

Baron, Frédéric ; Université de Liège - ULiège > I3-Hematology

Breems, D.; Department of Hematology, Ziekenhuis Netwerk, Antwerpen, Belgium

De Becker, A.; Department of Hematology, University Hospital, Vrije Universiteit Brussel, Brussels, Belgium

Graux, C.; Department of Hematology, University Hospital Namur, Université Catholique de Louvain, Belgium

Lewalle, Philippe

More authors (6 more)

Language :

English

Title :

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

Publication date :

2021

Journal title :

Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine

ISSN :

1784-3286

Publisher :

Taylor and Francis Ltd.

Volume :

Pages :

500-508

Peer reviewed :

Peer reviewed

Available on ORBi :

since 29 January 2021

Statistics

Number of views

175 (6 by ULiège)

Number of downloads

368 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant. 2005 Jan; 35 (2): 107–119. Review.
Clark JR, Scott SD, Jack AL, et al. United Kingdom national external quality assessment service for leucocyte immunophenotyping chimerism working group. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working Group. Br J Haematol. 2015 Jan; 168 (1): 26–37.
Sellmann L, Rabe K, Bünting I, et al. Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. Bone Marrow Transplant. 2018 Nov; 53 (11): 1457–1465.
Bader P. Documentation of engraftment and chimerism after HSCT. In: Carreras E, Dufour C, Mohty M, et al., editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Cham (Switserland): Springer Open; 2019. p. 143–147.
Miura Y, Tanaka J, Toubai T, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transplant. 2006 May; 37 (9): 837–843.
Valcárcel D, Sureda A. Graft Failure. In: Carreras E, Dufour C, Mohty M, et al., editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Cham (Switserland): Springer Open; 2019. p. 143–147.
Kröger N, Bacher U, Bader P, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16 (10): 1325–1346.
Lion T, Watzinger F, Preuner S, et al. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia. 2012 Aug; 26 (8): 1821–1828.
Ahci M, Stempelmann K, Buttkereit U, et al. Clinical utility of quantitative PCR for chimerism and engraftment monitoring after allogeneic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017 Oct; 23 (10): 1658–1668.
Khan F, Agarwal A, Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant. 2004 Jul; 34 (1): 1–12. Review.
Acquaviva C, Duval M, Mirebeau D, et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Paris-Robert Debré experience. Leukemia. 2003 Jan; 17 (1): 241–246.
Chia WC, Khoo TS, SFS AW, et al. Multiplex STR panel for assessment of chimerism following hematopoietic stem cell transplantation (HSCT). Ann Hematol. 2019 May; 98 (5): 1279–1291.
Schraml E, Daxberger H, Watzinger F, et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Vienna experience. Leukemia. 2003 Jan; 17 (1): 224–227. Review.
Alizadeh M, Bernard M, Danic B, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002 Jun 15; 99 (12): 4618–4625.
Frankfurt O, Zitzner JR, Tambur AR. Real-time qPCR for chimerism assessment in allogeneic hematopoietic stem cell transplants from unrelated adult and double umbilical cord blood. Hum Immunol. 2015 Mar; 76 (2–3): 155–160.
Kletzel M, Huang W, Olszewski M, et al. Validation of chimerism in pediatric recipients of allogeneic hematopoietic stem cell transplantation (HSCT) a comparison between two methods: real-time PCR (qPCR) vs. variable number tandem repeats PCR (VNTR PCR). Chimerism. 2013 Jan-Mar; 4 (1): 1–8.
Kim SY, Jeong MH, Park N, et al. Chimerism monitoring after allogeneic hematopoietic stem cell transplantation using quantitative real-time PCR of biallelic insertion/deletion polymorphisms. J Mol Diagn. 2014 Nov; 16 (6): 679–688.
Willasch AM, Kreyenberg H, Shayegi N, et al. Monitoring of hematopoietic chimerism after transplantation for pediatric myelodysplastic syndrome: real-time or conventional short tandem repeat PCR in peripheral blood or bone marrow? Biol Blood Marrow Transplant. 2014 Dec; 20 (12): 1918–1925.
Koldehoff M, Steckel NK, Hlinka M, et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol. 2006 Oct; 81 (10): 735–746.
Stahl T, Böhme MU, Kröger N, et al. Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. Exp Hematol. 2015 Jun; 43 (6): 462–468.
Thiede C, Bornhäuser M, Ehninger G. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004; 112 (1–2): 16–23.
Davis BH, Dasgupta A, Kussick S, et al. ICSH/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues. Cytometry B Clin Cytom. 2013 Sep-Oct; 84 (5): 286–290.
Borill V, Schlaphoff T, Du Toit E, et al. The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report. Hematology. 2008 Aug; 13 (4): 210–214.
Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004 Oct 15; 104 (8): 2254–2262.
Koreth J, Kim HT, Nikiforow S, et al. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20 (10): 1516–1521.
Reshef R, Hexner EO, Loren AW, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov; 20 (11): 1758–1766.
Storb R, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2016 May; 101 (5): 521–530.
Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev. 2005 May; 19 (3): 153–164.
Lee KH, Lee JH, Choi SJ, et al. Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2003 Aug; 32 (4): 423–431.
Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999 Nov 1; 94 (9): 3234–3241.
Thompson PA, Stingo F, Keating MJ, et al. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 May; 177 (4): 567–577.
Huisman C, de Weger RA, de Vries L, et al. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant. 2007 Mar; 39 (5): 285–291. Epub 2007 Jan 29
Breuer S, Preuner S, Fritsch G, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2012 Mar; 26 (3): 509–519.
Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev. 2002 Jun; 16 (2): 81–85.
Severe Aplastic Anaemia Working Party of the European Blood and Marrow Transplant Group, Lawler M, McCann SR, Marsh JC, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol. 2009 Mar; 144 (6): 933–945.
Gaziev J, Lucarelli G. Stem cell transplantation for hemoglobinopathies. Curr Opin Pediatr. 2003 Feb; 15 (1): 24–31.
Hoelle W, Beck JF, Dueckers G, et al. Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia. Bone Marrow Transplant. 2004 Jan; 33 (2): 219–223.
Chen CT, Gau JP, Liu JH, et al. Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia. J Chin Med Assoc. 2018 Dec; 81 (12): 1038–1043.
Wiedemann B, Klyuchnikov E, Kröger N, et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol. 2010 Dec; 38 (12): 1261–1271.
Gabr H, Youssry I, El-Ansary Y, et al. Chimerism in pediatric hematopoietic stem cell transplantation and its correlation with the clinical outcome. Transpl Immunol. 2017 Dec; 45: 53–58.
Lassaletta A, Ramírez M, Montero JM, et al. Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Leukemia. 2005 Apr; 19 (4): 504–506.
Kern W, Haferlach C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer. 2008 Jan 1; 112 (1): 4–16.
Hertenstein B, Hambach L, Bacigalupo A, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation–a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005 Jul; 90 (7): 969–975.
Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011; 17 (6): 771–789.
Herens C, Brasseur E, Jamar M, et al. Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukaemia and preleukaemia. Clin Lab Haematol. 1999 Feb; 21 (1): 17–20.
Stone JF, Sandberg AA. Sex chromosome aneuploidy and aging. Mutat Res. 1995 Oct; 338 (1–6): 107–113.
Abraham A, Hsieh M, Eapen M, et al. Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017 Dec; 23 (12): 2178–2183.
Stikvoort A, Sundin M, Uzunel M, et al. Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant? PLoS One. 2016 May 6; 11 (5): e0154737.
Willasch A, Hoelle W, Kreyenberg H, et al. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica. 2006 Jun; 91 (6): 788–794.
Stikvoort A, Gertow J, Sundin M, et al. Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. Biol Blood Marrow Transplant. 2013 May; 19 (5): 83844.
Faraci M, Bagnasco F, Leoni M, et al. Evaluation of chimerism dynamics after allogeneic hematopoietic stem cell transplantation in children with nonmalignant diseases. Biol Blood Marrow Transplant. 2018 May; 24 (5): 1088–1093.
Caldemeyer LE, Akard LP, Edwards JR, et al. Donor lymphocyte infusions used to treat mixed-chimeric and high-risk patient populations in the relapsed and nonrelapsed settings after allogeneic transplantation for hematologic malignancies are associated with high five-year survival if persistent full donor chimerism is obtained or maintained. Biol Blood Marrow Transplant. 2017 Nov; 23 (11): 1989–1997.
Alyea EP, DeAngelo DJ, Moldrem J, et al. NCI First international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Aug; 16 (8): 1037–1069.
Rujkijyanont P, Morris C, Kang G, et al. Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J. 2013 Aug; 30 (3): e137.
Rettinger E, Willasch AM, Kreyenberg H, et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood. 2011 Nov 17; 118 (20): 5681–5688. Epub 2011 Sep 26.
Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015 Feb; 21 (2): 288–292.
Preuner S, Peters C, Pötschger U, et al. Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute fpl leukemia. Haematologica. 2016 Jun; 101 (6): 741–746.
Thiede C, Lutterbeck K, Oelschlägel U, et al. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. Ann Hematol. 2002; 81 (Suppl 2): S27–8.
Bornhäuser M, Oelschlaegel U, Platzbecker U, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica. 2009 Nov; 94 (11): 1613–1617.
Unnikrishnan A, Meacham AM, Goldstein SS, et al. CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation. Leuk Res. 2018 Nov; 74: 110–112.
Hoffmann JC, Stabla K, Burchert A, et al. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. Ann Hematol. 2014 Feb; 93 (2): 279–285.
Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005 Mar 20; 23 (9): 1993–2003.
Broglie L, Helenowski I, Jennings LJ, et al. Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant. Pediatr Blood Cancer. 2017 Sep;64(9).
Pichler H, Fritsch G, König M, et al. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter? Br J Haematol. 2016 Jun; 173 (6): 905–917.
Lee HC, Saliba RM, Rondon G, et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015 Nov; 21 (11): 1948–1954.
Rauwerdink CA, Tsongalis GJ, Tosteson TD, et al. The practical application of chimerism analyses in allogeneic stem cell transplant recipients: blood chimerism is equivalent to marrow chimerism. Exp Mol Pathol. 2012 Dec; 93 (3): 339–344.